Aspirin Resistance: A Review Of Diagnostic Methodology, Mechanisms, and Clinical Utility

Advances in Clinical Chemistry

Volumn 42, Issue , 2006, Pages 81-110

  Schwartz, Kenneth A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DRUG RESISTANCE; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG RESISTANCE; HUMANS;

EID: 33748031760     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(06)42003-5     Document Type: Review

References (68)

1. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324 (2002) 71-86
2. ATC. Collaborative overview of randomised trials of antiplatelet therapy, Part I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308 (1994) 81-106
3. ATC. Collaborative overview of randomised trials of antiplatelet therapy, Part II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 308 (1994) 159-168
4. ATC. Collaborative overview of randomised trials of antiplatelet therapy, Part III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 308 (1994) 235-246
5. Schwartz K., Schwartz D., Ghosheh K., Reeves M., Barber K., and De Franco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
6. Catella-Lawson F., Reilly P., Kapoor S., Cucchiara A., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 25 (2001) 1809-1817
7. RISC. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990) 827-830
8. Lewis H., Davis J., Archibald D., Steinkex W., Smitheran T., Doherty J., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309 (1983) 396-403
9. Watala C., Golanski J., Pluta J., Boncler M., Rozalski M., Luzak B., et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): Its relation to metabolic control. Thromb Res 113 (2004) 101-113
10. Gum P., Kottke-Marchant K., Welsh P., White J., and Topol E. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 6 (2003) 961-965
11. Eikelboom J., Hirsh J., Weitz J., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 14 (2002) 1650-1655
12. Grotemeyer K., Scharafinski H., and Husstedt I. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
13. Roth G., and Calverley D. Aspirin, platelets, and thrombosis: Theory and practice. Blood 83 4 (1994) 885-898
14. Altman R., Luciardi H., Muntaner J., and Herrera R. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?. Thromb J 2 1 (2004) 1-8
15. Ezratty A., Freedman J., Simon D., and Loscalzo J. The antithrombotic effects of acetylation of fibrinogen by aspirin. J Vasc Med Biol 5 4 (1994) 152-159
16. Kharbanda R., Walton B., Allen M., Klein N., Hingorani A., MacAllister R., et al. Prevention of inflammation-induced endothelial dysfunction. Circulation 105 (2002) 2600-2604
17. Ridker P., Cushman M., Stampfer M., Tracy R., and Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently health men. N Engl J Med 336 14 (1997) 973-979
18. Packham M., Rand M., and Kinlough-Rathbone R. Aggregation. In: Gresele P., Page C., Fuster V., and Vermylen J. (Eds). Platelets in Thrombotic and Non-thrombotic Disorders. Ist ed. (2002), Cambridge University Press, Cambridge 338-356
19. Roberts J., and Morrow J. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout (Chapter 27). In: Hardman J., and Limbird L. (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill, New York 16-18
20. Pedersen A., and FitzGerald G. Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311 19 (1984) 1206-1211
21. Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O., et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin?. Am Heart J 147 2 (2004) 293-300
22. Zucker M. In vitro studies of the platelet agggregation-release reaction. Current concepts of cerebrovascular disease. Stroke 7 (1972) 21-24
23. Chakroun T., Gerotziafas G., Robert F., Lecrubier C., Samama M., Hatmi M., et al. In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 124 1 (2004) 80-85
24. Schwartz K., Schwartz D., Pittsley R., Mantz S., Ens G., Sami A., et al. A new method for measuring inhibition of platelet function by nonsteroidal anti-inflammatory drugs. J Lab Clin Med 139 4 (2002) 227-233
25. Gum P., Kottke-Marchant K., Poggio E., Gurm H., Welsch P., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
26. Sane D., McKee S., Malinin A., and Serebruany V. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 90 8 (2002) 893-895
27. Williams H., Howard R., O'Donnell N., and Findley I. The effect of low dose aspirin on bleeding times. Anaesthesia 48 (1993) 331-333
28. Thiagarajan P., and Wu K. In vitro assays for evaluating platelet funtion. In: Gresele P., Page C., Fuster V., and Vermylen J. (Eds). Platelets in Thrombotic and Nonthrombotic Disorders (2002), Cambridge University Press, Cambridge 459-470
29. BSHHTTF. Guidelines on platelet function testing. J Clin Pathol 41 (1988) 1322-1330
30. Harker L., and Slichter S. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287 (1972) 155-159
31. Mammen E., Comp P., Gosselin R., Greenberg C., Hoots W., Kessler C., et al. PFA-100(tm) system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 24 2 (1998) 195-202
32. Homoncik M., Blann A., Hollenstein U., Pernerstorfer T., Eichler H., and Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111 (2000) 1250-1252
33. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2003) 37-42
34. Topel E., and Gum P. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease (letter). J Am Coll Cardiol 42 (2003) 1336-1337
35. Smith J., Steinhubl S., Lincoff A., Coleman J., Lee T., Hillman R., et al. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
36. Malinin A., Spergling M., Muhlestein B., Steinhubl S., and Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 4 (2004) 295-301
37. Malinin A., Atar D., Callahan K., McKenzie M., and Serebruanay V. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol 462 (2003) 139-143
38. Wang J., Aucoin-Barry D., Manuelian D., Monbouquette R., Reisman M., Gray W., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 12 (2003) 1492-1494
39. Rao G., Johnston G., Reddy K., and White J. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Atherosclerosis 3 (1983) 383-388
40. Komiya T., Kudo M., Urabe T., and Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke 25 12 (1994) 2337-2342
41. Kurth T., Glynn R., Walker A., Chan K., Buring J., Hennekens C., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
42. Kawasaki T., Ozeki Y., Igawa T., and Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31 (2000) 591-595
43. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 1-2 (2002) 45-49
44. Valles J., Santos M., Aznar J., Martinez M., Moscardo A., Pinon M., et al. Platelet-erythrocyte interactions enhance IIbB3 intergrin receptor activation and P-selectin expression during platelet recruitment: Down-regulation by aspirin ex vivo. Blood 99 (2002) 3978-3984
45. Valles J., Santos T., Aznar J., Osa A., Lago A., Cosin J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation 97 (1998) 350-355
46. Reilly I., and FitzGerald G. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69 1 (1987) 180-186
47. Hawkey C. COX-2 inhibitors. Lancet 353 (1999) 307-314
48. Weber A., Zinmmermann K., Meyer-Kirchrath J., and Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 353 (1999) 900
49. Hankey G., and Eikelboom J. Aspirin resistance. Br Med J 328 (2004) 477-479
50. Patrignani P., Sciulli M., Manarini S., Santini G., Cerletti C., and Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 50 4 (1999) 661-667
51. Larsson P., Wallen N., and Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 89 5 (1994) 1951-1957
52. Wallen N., Heldt C., Rehnqvist N., and Hjemdah I. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 18 (1997) 807-815
53. Christiaens L., Macchi L., Herpin D., Cosine D., C., Allah J., et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 108 (2003) 115-119
54. Cambria-Kiely J., and Gandhi P. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 14 1 (2002) 51-58
55. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104 (2001) 2666-2672
56. Szczeklik A., Undas A., Sanak M., Frolow M., and Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 110 (2000) 965-967
57. A1 (GP IIIa) polymorphism but not with C807T (GP Ia/IIa) and C-5T kozak (GP Ib) polymorphisms. J Am Coll of Cardiol 42 6 (2003) 1115-1119
58. A2 polymorphism and efficacy of aspirin. Lancet 351 (1998) 1253
59. Csiszar A., Stef G., Pacher P., and Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 557-558
60. Cipollone F., Ciabattoni G., Patrignami P., Pasquale M., DiGregorio D., Bucciarelli T., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 (2000) 1007-1013
61. Schwartz K., Schwartz D., Barber K., Reeves M., Hall J., and De Franco A. Relationship between risk factors for coronary artery disease and aspirin resistance. Blood 104 (2004) 513a (abstract #1854)
62. Wilson P., D'Agostino R., Levy D., Belanger A., Silbershatz H., and Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
63. Tamminen M., Lassila R., Westerbacka J., Vehkavaara S., and Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obesity 27 8 (2003) 907-911
64. Friend M., Vucenik I., and Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. Br Med J 326 (2003) 82-83
65. Hung J., Lam J., Lacoste L., and Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
66. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
67. Helgason C., Tortorice K., Winkler S., Penney D., Schuler J., McClelland T., et al. Aspirin response and failure in cerebral infarction. Stroke 24 3 (1993) 345-350
68. Payne D., Jones C., Hayes P., Webster S., Naylor A., and Goodall A. Platelet inhibition by aspirin is diminished in patients during carotid surgery: A form of transient aspirin resistance?. Thromb Haemost 92 (2004) 89-96